Suche
Filter by content type
Filter by content year
BioNTech Publishes Final Results of the Exchange Offer for CureVac
Dezember 18, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … are cautioned that any such forward-looking statements are based on BioNTech’s current beliefs and expectations … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
Dezember 18, 2025 - … strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … are cautioned that any such forward-looking statements are based on BioNTech’s current beliefs and expectations …
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Dezember 9, 2025 - … TNBC determined ineligible for PD-(L)1 therapy based on PD-L1 negative disease. Pumitamig is also being … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of …
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge
Dezember 6, 2025 - … incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 24(11):1206-1218. 7 Hu, Sheng et … Analysis of 922,217 Lung Cancer Patients from the US Based on the Most Recent Data from the SEER Database (April … incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 24(11):1206-1218. 7 Hu, Sheng et …
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Dezember 6, 2025 - … had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy. Data from the non-pivotal stage of the … who have progressed on PD-(L)1 inhibitors and platinum-based chemotherapy. The non-pivotal stage of the trial … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
Dezember 3, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … are cautioned that any such forward-looking statements are based on BioNTech’s or CureVac’s current beliefs and … France, Italy, the Netherlands and Spain, in each case based on the EU Prospectus, except that BioNTech ADSs may be …
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
November 26, 2025 - … Share (“ADS”) for each CureVac share, determined based on the volume-weighted average price of BioNTech ADSs … CureVac share. This calculation of the Exchange Ratio is based on the volume weighted average price of a BioNTech ADS … is extended, BioNTech will recalculate the Exchange Ratio based on the later expected final expiration time and …
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
November 3, 2025 - … the 2025 financial year. The Company’s approach to revenue recognition, including the amount and timing of revenues, is based on the facts and circumstances known to the Company and … who have previously received trastuzumab and a taxane-based chemotherapy met its primary endpoint of PFS at a …
BioNTech to Host Innovation Series R&D Day on November 11, 2025
Oktober 28, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Oktober 27, 2025 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
